PROTEIN BASED VACCINES

Novavax shares slump premarket on worries over prospects

The company, which reported fourth-quarter earnings late on Tuesday, flagged significant uncertainty around its 2023 revenue, funding from the U.S. government, and pending arbitration with global vaccine alliance Gavi. Novavax's vaccine was meant to convince those skeptical about mRNA shots from rivals Moderna and Pfizer-BioNTech to get immunized, but manufacturing and regulatory delays led to sluggish uptake in key markets.